Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.18 -0.68 (-0.68%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
95 96 Next >
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns. 
Via Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Smart Money Is Betting Big In MRK Options
Via Benzinga
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck & Co Inc. DCF Valuation: Is The Stock Undervalued?
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. 
Via Talk Markets
Merck & Co's Options Frenzy: What You Need to Know
Via Benzinga
Evaluating Merck &amp; Co Against Peers In Pharmaceuticals Industry
Via Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... 
Via Benzinga
Exposures COVID-19
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck stock is down more than 4% after lowering its 2024 earnings outlook, but if you look beyond the headline numbers, this could be a chance to buy the dip 
Via MarketBeat
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q2 2024
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
4 Stocks to Keep High on Your Buy List
Be ready for opportunities. 
Via The Motley Fool
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises... 
Via Benzinga
Exposures Product Safety
Nasdaq, S&P Futures Rise As Microsoft, AMD Earnings Take Spotlight: Will Fed Provide 'Turbo Boost' For Market? Analyst Weighs In
Wall Street is likely to tenaciously hold onto the slender optimism ahead of a slew of earnings from notable companies and the Federal Reserve’s two-day rate-setting meeting that gets underway on... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short
Merck reported better-than-expected earnings on Tuesday. But the pharmaceutical giant's soft outlook could pressure Merck stock. 
Via Investor's Business Daily
Merck Announces Second-Quarter 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Earnings Divide Dow Industrials As Crux Of Q2 Season Approaches
The Dow index declined 1.3% on Wednesday, undercutting short-term support. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints. 
Via Benzinga
Merck Announces Fourth-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
From Merck & Co., Inc.
Via Business Wire
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
This fund has a basket of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
Merck secures legal victory as 3rd U.S. Circuit Court of Appeals upholds dismissal of 1,200 lawsuits over Zostavax shingles vaccine. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
2 Magnificent Stocks to Buy With $500
These reliable healthcare companies look attractive no matter how you slice it. 
Via The Motley Fool
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.